180 Life Sciences Corp. (ATNF)
NASDAQ: ATNF · Real-Time Price · USD
0.8610
-0.0090 (-1.03%)
Apr 23, 2025, 4:00 PM EDT - Market closed

Company Description

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases.

The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and α7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor.

The company is headquartered in Palo Alto, California.

180 Life Sciences Corp.
180 Life Sciences logo
Country United States
Founded 2016
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Lloyd Jordan

Contact Details

Address:
Building 4, Suite 200
Palo Alto, California 94306
United States
Phone 650 507 0669
Website 180lifesciences.com

Stock Details

Ticker Symbol ATNF
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001690080
CUSIP Number 68236V104
ISIN Number US68236V3024
Employer ID 81-3832378
SIC Code 2834

Key Executives

Name Position
Lloyd Blair Jordan L.L.B., M.B.A. Chief Executive Officer and Director
Sir Marc Feldman Ph.D. Co-Founder
Dr. Lawrence Steinman BA, M.D., Ph.D. Co-Founder and Director
Prof. Jagdeep Nanchahal M.D., Ph.D. Co-Founder and Chairman of Clinical Advisory Board
Eric R. Van Lent CAO, Principal Accounting and Financial Officer

Latest SEC Filings

Date Type Title
Apr 16, 2025 SCHEDULE 13G Filing
Apr 11, 2025 SCHEDULE 13D/A Filing
Apr 9, 2025 8-K Current Report
Apr 1, 2025 8-K/A [Amend] Current report
Mar 31, 2025 10-K Annual Report
Feb 25, 2025 SCHEDULE 13D Filing
Feb 25, 2025 8-K Current Report
Feb 21, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G Filing
Feb 13, 2025 SCHEDULE 13G Filing